Objectives To compare the efficacy and tolerability of transdermal buprenorphine in elderly
patients and 2 younger populations, all requiring analgesic treatment for moderate-to-severe …

Results Out of 1,188 patients with known age, 564 were under 65, 337 were between 65
and 75, and 287 were over 75 years. Within these respective age groups, 63.9%, 66.3% and …

Objective: To assess patients' perceptions regarding the low-dose 7-day buprenorphine
transdermal patch for treatment of moderate non-malignant chronic pain. Methods: Patient …

Purpose Transdermal buprenorphine patches provide comparable pain relief to that of low-
potency opioids in elderly individuals. However, specific data on their use in elderly …

Objective: A recent pharmacokinetic study with buprenorphine transdermal patches showed
similar systemic exposures of buprenorphine in subjects aged≥ 75 and 50–60 years. The …

Background: Musculoskeletal pathologies are among the most frequent causes of long-term
non-oncological severe pain and consequent physical impairment. Aims of pharmacological …

Chronic pain in the elderly is a significant problem. Pharmacokinetic and metabolic changes
associated with increased age makes the elderly vulnerable to side effects and overdosing …

CONTEXT: Chronic pain increases with age, and in the elderly, comorbidities and
polypharmacotherapy make the choice of treatment for pharmacological pain control a …

BACKGROUND:: Buprenorphine, a potent opioid analgesic, has been available in
parenteral and oral or sublingual (SL) formulations for> 25 years. In 2001, the …

Abstract▴ Buprenorphine is a low molecular weight, lipophilic, opioid analgesic. Recently, a
transdermal matrix patch formulation of buprenorphine has become available in three …